iCAD to Showcase Use of Artificial Intelligence in Medical Imaging
at RSNA 2016
Company highlighting latest in deep learning technology used to detect cancer earlier and
NASHUA, NH and CHICAGO – November 28, 2016 - iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early detection and treatment of cancer, today announced the Company will highlight its suite of advanced cancer detection and workflow tools, including PowerLook® Mammo Detection, PowerLook® Density Assessment, PowerLook Tomo Detection* and VeraLook® CTC colon polyp detection technology at its booth #4129 in the South Hall at RSNA 2016. iCAD’s PowerLook Tomo Detection, designed to improve digital breast tomosynthesis reading workflow, has CE Mark and is installed at multiple facilities in Europe and is approved for sale in Canada. It is currently pending FDA approval.
Also during the meeting, research will be presented at two separate sessions that focus on utilizing the PowerLook Tomo Detection workflow solution. To learn more information about the data presented during the meeting, please visit http://go.icadmed.com/RSNA2016.
*iCAD tomosynthesis solutions are investigational devices in the US and limited by US Federal Law to investigational use.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
For iCAD investor relations:
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
Sales & Services
+1 866 280 2239